Stocks In News - Expansion

1. Glenmark Pharma has secured marketing authorization in Germany for its generic version of Seretide Accuhaler.
2. The company's subsidiary Glenmark Arzneimittel GmbH has secured marketing authorization in Germany for fluticasone/salmeterol dry powder inhaler (DPI), a generic version of GlaxoSmithKline’s Seretide Accuhaler.
3. Fluticasone/salmeterol DPI is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
4. Glenmark will sell the product in Germany under the name SALFLUTIN.